Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13542091 | 0.89 | PKM (0.51) | PKMHTTALDH1A1POLBMEN1 | |
| SCHEMBL29277880 | 0.86 | PKM (0.49) | PKMHTTALDH1A1POLBMEN1 | |
| SCHEMBL31629999 | 0.83 | PKM (0.61) | PKMHTTALDH1A1POLBMEN1 | |
| SCHEMBL12330364 | 0.83 | PKM (0.61) | PKMHTTALDH1A1POLBMEN1 | |
| SCHEMBL29657316 | 0.83 | PKM (0.61) | PKMHTTALDH1A1POLBMEN1 | |
| SCHEMBL16019510 | 0.83 | MEN1 (0.62) | PKMHTTALDH1A1POLBMEN1 | |
| SCHEMBL19011448 | 0.81 | PKM (0.59) | PKMHTTALDH1A1POLBMEN1 | |
| SCHEMBL21510196 | 0.81 | PKM (0.59) | PKMHTTALDH1A1POLBMEN1 | |
| SCHEMBL17277538 | 0.81 | PKM (0.59) | PKMHTTALDH1A1POLBMEN1 | |
| SCHEMBL896732 | 0.81 | PKM (0.54) | PKMHTTALDH1A1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | UCB PHARMA, S.A. (BE) | 2010-01-14 | — | — | US | disclosed |
| EP-2049548-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB Pharma, S.A. (BE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008012010-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB PHARMA, S.A. (BE) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | HRH3, HRH4, HRH2 | PKM 1594/4885HTT 1663/4885ALDH1A1 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.